Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + exemestane versus capecitabine in HR-positive/HER2-negative metastatic breast cancer resistant to non-steroidal aromatase inhibitors
2013-003170-27Phase 3Completed
- Sponsor
- GEICAM
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Progression-Free Survival. Started Oct 2013; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-003170-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003170-27.